Skip to content

Treatment of Dermatophytosis (Ringworm) with Unani medicine Majoon-e-Ushba and Marham Qooba

Clinical Validation of Unani Pharmacopoeial formulations Majoon-e- Ushba and Marham Qooba in Qooba (Dermatophytosis)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017857
Enrollment
240
Registered
2019-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B359- Dermatophytosis, unspecified

Interventions

Intervention1: Majoon-e- Ushba and Marham Qooba: Majoon-e- Ushba 10 g Twice daily Orally with water for 5 weeks Marham Qooba Q.S. Twice daily Topically on the affected area after rubbing for few secon

Sponsors

Central Council for Research in Unani Medicine CCRUM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged between 18- 65 years 2. Subjects with KOH positive/microscopically confirmed 3. Clinical signs and symptoms suggestive of fungal infection viz. annular / arcuate polycyclic lesion with clear centre and an active margin with papulo-vesicles & scaling; erythema, itching, burning.

Exclusion criteria

Exclusion criteria: 1. Patients of either sex 65 years 2. Superficial skin disease like Eczema/psoriasis/scabies 3. Superadded infections 4. Lactating and pregnant women 5. Subjects with Tinea capitis (tinea of scalp), Onychomycosis (tinea of nails) and Tinea barbae (tinea of beard) 6. Subjects who are concomitantly using any anti-fungal product in any form 7. Known cases of allergy to any ingredients of the study drug 8. Subjects with systemic diseases requiring long-term treatment 9. Subjects not willing to undergo the specified washout periods (for topical preparations not less than 2 weeks & for systemic medicines 4 weeks)

Design outcomes

Primary

MeasureTime frame
Improvement in sign and symptoms of Qooba (Dermatophytosis)Timepoint: 05 weeks.

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026